The Innovative Medicines Initiative moves translational immunology forward

The Innovative Medicines Initiative moves translational immunology forward

The Innovative Medicines Initiative (IMI) was established in 2008 as a public‐private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations with the mission to promote the development of novel therapies through collaborative efforts based on...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of immunology 2013-02, Vol.43 (2), p.298-302
Hauptverfasser: Goldman, Michel, Wittelsberger, Angela, De Magistris, Maria‐Teresa
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Animals
Cooperative Behavior
Drug Industry
Humans
Public-Private Sector Partnerships
Translational Medical Research
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 302
container_issue 2
container_start_page 298
container_title European journal of immunology
container_volume 43
creator Goldman, Michel
Wittelsberger, Angela
De Magistris, Maria‐Teresa
description The Innovative Medicines Initiative (IMI) was established in 2008 as a public‐private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations with the mission to promote the development of novel therapies through collaborative efforts based on the concept of pre‐competitive research. Several consortia supported by IMI are dedicated to immuno‐inflammatory disorders, immune‐based biopharmaceuticals and vaccines. Herein, we present the key principles underlying IMI, briefly review the status of projects related to translational immunology, and present future topics of interest to immunologists.
doi_str_mv 10.1002/eji.201370024
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1321335172</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2891098471</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4084-367d9fc919cdcd3fabe4ac330f234af81c6675685d715c736722a0e279c5ad303</originalsourceid><addsrcrecordid>eNp90M1LwzAYBvAgipvTo1cZePHSmTcfTXOUMXVj4mWeS5ammtE2M1k39t-b0angwVN4H348hAeha8AjwJjcm5UdEQxUxIOdoD5wAgkDBqeojzGwhMgM99BFCCuMsUy5PEc9QjllOIU-mi0-zHDaNG6rNnZrhi-msNo2JsTQbmwX1m4bg41XTahi4hpVDW1dt42r3Pt-WDq_U764RGelqoK5Or4D9PY4WYyfk_nr03T8ME80wxlLaCoKWWoJUhe6oKVaGqY0pbgklKkyA52mgqcZLwRwLSInRGFDhNRcFRTTAbrretfefbYmbPLaBm2qSjXGtSEHSoBSDoJEevuHrlzr4_ejIpmgXEo4qKRT2rsQvCnztbe18vsccH4YOY8j5z8jR39zbG2XtSl-9PeqEYgO7Gxl9v-35ZPZ9Lf6C2PjhxQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1287359912</pqid></control><display><type>article</type><title>The Innovative Medicines Initiative moves translational immunology forward</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><creator>Goldman, Michel ; Wittelsberger, Angela ; De Magistris, Maria‐Teresa</creator><creatorcontrib>Goldman, Michel ; Wittelsberger, Angela ; De Magistris, Maria‐Teresa</creatorcontrib><description>The Innovative Medicines Initiative (IMI) was established in 2008 as a public‐private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations with the mission to promote the development of novel therapies through collaborative efforts based on the concept of pre‐competitive research. Several consortia supported by IMI are dedicated to immuno‐inflammatory disorders, immune‐based biopharmaceuticals and vaccines. Herein, we present the key principles underlying IMI, briefly review the status of projects related to translational immunology, and present future topics of interest to immunologists.</description><identifier>ISSN: 0014-2980</identifier><identifier>EISSN: 1521-4141</identifier><identifier>DOI: 10.1002/eji.201370024</identifier><identifier>PMID: 23534061</identifier><identifier>CODEN: EJIMAF</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>Allergy and Immunology ; Animals ; Cooperative Behavior ; Drug Industry ; Humans ; Public-Private Sector Partnerships ; Translational Medical Research</subject><ispartof>European journal of immunology, 2013-02, Vol.43 (2), p.298-302</ispartof><rights>2013 WILEY‐VCH Verlag GmbH &amp; Co. KGaA, Weinheim</rights><rights>2013 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4084-367d9fc919cdcd3fabe4ac330f234af81c6675685d715c736722a0e279c5ad303</citedby><cites>FETCH-LOGICAL-c4084-367d9fc919cdcd3fabe4ac330f234af81c6675685d715c736722a0e279c5ad303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Feji.201370024$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Feji.201370024$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,1428,27905,27906,45555,45556,46390,46814</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23534061$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goldman, Michel</creatorcontrib><creatorcontrib>Wittelsberger, Angela</creatorcontrib><creatorcontrib>De Magistris, Maria‐Teresa</creatorcontrib><title>The Innovative Medicines Initiative moves translational immunology forward</title><title>European journal of immunology</title><addtitle>Eur J Immunol</addtitle><description>The Innovative Medicines Initiative (IMI) was established in 2008 as a public‐private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations with the mission to promote the development of novel therapies through collaborative efforts based on the concept of pre‐competitive research. Several consortia supported by IMI are dedicated to immuno‐inflammatory disorders, immune‐based biopharmaceuticals and vaccines. Herein, we present the key principles underlying IMI, briefly review the status of projects related to translational immunology, and present future topics of interest to immunologists.</description><subject>Allergy and Immunology</subject><subject>Animals</subject><subject>Cooperative Behavior</subject><subject>Drug Industry</subject><subject>Humans</subject><subject>Public-Private Sector Partnerships</subject><subject>Translational Medical Research</subject><issn>0014-2980</issn><issn>1521-4141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90M1LwzAYBvAgipvTo1cZePHSmTcfTXOUMXVj4mWeS5ammtE2M1k39t-b0angwVN4H348hAeha8AjwJjcm5UdEQxUxIOdoD5wAgkDBqeojzGwhMgM99BFCCuMsUy5PEc9QjllOIU-mi0-zHDaNG6rNnZrhi-msNo2JsTQbmwX1m4bg41XTahi4hpVDW1dt42r3Pt-WDq_U764RGelqoK5Or4D9PY4WYyfk_nr03T8ME80wxlLaCoKWWoJUhe6oKVaGqY0pbgklKkyA52mgqcZLwRwLSInRGFDhNRcFRTTAbrretfefbYmbPLaBm2qSjXGtSEHSoBSDoJEevuHrlzr4_ejIpmgXEo4qKRT2rsQvCnztbe18vsccH4YOY8j5z8jR39zbG2XtSl-9PeqEYgO7Gxl9v-35ZPZ9Lf6C2PjhxQ</recordid><startdate>201302</startdate><enddate>201302</enddate><creator>Goldman, Michel</creator><creator>Wittelsberger, Angela</creator><creator>De Magistris, Maria‐Teresa</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201302</creationdate><title>The Innovative Medicines Initiative moves translational immunology forward</title><author>Goldman, Michel ; Wittelsberger, Angela ; De Magistris, Maria‐Teresa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4084-367d9fc919cdcd3fabe4ac330f234af81c6675685d715c736722a0e279c5ad303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Allergy and Immunology</topic><topic>Animals</topic><topic>Cooperative Behavior</topic><topic>Drug Industry</topic><topic>Humans</topic><topic>Public-Private Sector Partnerships</topic><topic>Translational Medical Research</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goldman, Michel</creatorcontrib><creatorcontrib>Wittelsberger, Angela</creatorcontrib><creatorcontrib>De Magistris, Maria‐Teresa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goldman, Michel</au><au>Wittelsberger, Angela</au><au>De Magistris, Maria‐Teresa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Innovative Medicines Initiative moves translational immunology forward</atitle><jtitle>European journal of immunology</jtitle><addtitle>Eur J Immunol</addtitle><date>2013-02</date><risdate>2013</risdate><volume>43</volume><issue>2</issue><spage>298</spage><epage>302</epage><pages>298-302</pages><issn>0014-2980</issn><eissn>1521-4141</eissn><coden>EJIMAF</coden><abstract>The Innovative Medicines Initiative (IMI) was established in 2008 as a public‐private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations with the mission to promote the development of novel therapies through collaborative efforts based on the concept of pre‐competitive research. Several consortia supported by IMI are dedicated to immuno‐inflammatory disorders, immune‐based biopharmaceuticals and vaccines. Herein, we present the key principles underlying IMI, briefly review the status of projects related to translational immunology, and present future topics of interest to immunologists.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>23534061</pmid><doi>10.1002/eji.201370024</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0014-2980
ispartof European journal of immunology, 2013-02, Vol.43 (2), p.298-302
issn 0014-2980
1521-4141
language eng
recordid cdi_proquest_miscellaneous_1321335172
source MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content
subjects Allergy and Immunology
Animals
Cooperative Behavior
Drug Industry
Humans
Public-Private Sector Partnerships
Translational Medical Research
title The Innovative Medicines Initiative moves translational immunology forward
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T03%3A31%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Innovative%20Medicines%20Initiative%20moves%20translational%20immunology%20forward&rft.jtitle=European%20journal%20of%20immunology&rft.au=Goldman,%20Michel&rft.date=2013-02&rft.volume=43&rft.issue=2&rft.spage=298&rft.epage=302&rft.pages=298-302&rft.issn=0014-2980&rft.eissn=1521-4141&rft.coden=EJIMAF&rft_id=info:doi/10.1002/eji.201370024&rft_dat=%3Cproquest_cross%3E2891098471%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1287359912&rft_id=info:pmid/23534061&rfr_iscdi=true